DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,867,986 B2 Houze (45) Date of Patent: Jan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,867,986 B2 Houze (45) Date of Patent: Jan US007867986B2 (12) United States Patent (10) Patent No.: US 7,867,986 B2 Houze (45) Date of Patent: Jan. 11, 2011 (54) ENHANCED DRUG DELIVERY IN 5,780,050 A 7/1998 Jain et al. TRANSIDERMAL SYSTEMS 5,811,117 A 9, 1998 Hashimoto et al. 5,849,729 A * 12/1998 Zoumas et al. .............. 514,169 (75) Inventor: David Houze, Coconut Grove, FL (US) 5,898,032 A 4/1999 Hodgen 5,958,446 A * 9/1999 Miranda et al. ............. 424/448 (73) Assignee: Noven Pharmaceuticals, Inc., Miami, 6,024,974 A 2, 2000 Li FL (US) 6,143,319 A 11/2000 Meconi et al. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (21) Appl. No.: 10/330,361 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 30, 2002 CL 49-95 1, 1994 (65) Prior Publication Data US 2003/O152615A1 Aug. 14, 2003 (Continued) Related U.S. Application Data OTHER PUBLICATIONS (63) Continuation of application No. 09/948,107, filed on M.D. Mashkovsky, The Medicaments, Guidelines for Medical Doc Sep. 7, 2001, now abandoned. tors, vol. 1, 2001, 2 pgs... translation provided. (60) Provisional application No. 60/298,381, filed on Jun. (Continued) 18, 2001. Primary Examiner San-ming Hui (51) Int. Cl. 74) Attorney,V, AgAgent, or Firm—Foleyy & Lardner LLP A6 IK3I/56 (2006.01) (52) U.S. Cl. ...................................................... S14/171 (57) ABSTRACT (58) Field of Classification Search ................. 514/170, 514/171, 180 See application file for complete search history. A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of (56) References Cited a pharmaceutically active agent that includes a corresponding U.S. PATENT DOCUMENTS steroid and a steroid derivative; and a carrier for the pharma ceutically active agent. The Steroid and the corresponding 4,529,601 A 7/1985 Broberg et al. steroid derivative are present in a weight ratio of 10:1 to 1:10 4.585,452 A * 4, 1986 Sablotsky ................... 424/449 steroid: corresponding steroid derivative. In a preferred 4,906, 169 A 3, 1990 Chien et al. embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the 5,422,119 A 6/1995 Casper 5,474,783 A 12/1995 Miranda et al. corresponding Steroid derivative is a steroid ester. In another 5,633,242 A 5, 1997 Oettel et al. preferred embodiment, the carrier is a polymer that includes 5,656,386 A 8, 1997 Scherer et al. a pressure-sensitive adhesive. 5,711,962 A 1/1998 Cordes et al. 5,770.219 A * 6/1998 Chiang et al. ............... 424/448 33 Claims, 3 Drawing Sheets -- CombiPatch"Estradiol -OH- Combipatch"NETA, - A - Ex. Estradiol - Ex. 1 NET-NetA 48 time Hours) US 7,867,986 B2 Page 2 U.S. PATENT DOCUMENTS Office Action issued on Apr. 5, 2010 by the Examiner in U.S. Appl. No. 1 1/979.263 (US 2008/0167280). 6,149,935 A 11/2000 Chiang et al. 6,153,216 A 11/2000 Cordes et al. Office Action issued on Jul. 17, 2009 by the Examiner in U.S. Appl. 6,221,383 B1 4/2001 Miranda et al. No. 1 1/979.263 (US 2008/0167280). 6,303,141 B1 10/2001 Fischer et al. Office Action issued on Feb. 25, 2009 by the Examiner in U.S. Appl. 7,456,159 B2 11/2008 Houze et al. No. 1 1/979.263 (US 2008/0167280). 2003. O152613 A1 8, 2003 Houze Board of Patent Appeals and Interferences Decision issued on Mar. 2003. O152614 A1 8, 2003 Houze 16, 2010 by the Examiner in U.S. Appl. No. 10/330,360 (US 2003/ 2008.0167280 A1 7/2008 Houze et al. 0152614). 2008.0167365 A1 7/2008 Houze et al. Board of Patent Appeals and Interferences Decision issued on Mar. 16, 2010 by the Examiner in U.S. Appl. No. 10/330,279 (US 2003/ FOREIGN PATENT DOCUMENTS 0152613). CL 50-96 1, 1995 Notice of Allowance issued on May 1, 2008 by the Examiner in U.S. EP O 279 977 8, 1988 Appl. No. 10/330,281 (US 7456,159). EP O 294 601 B1 1, 1993 Office Action issued on Sep. 10, 2007 by the Examiner in U.S. Appl. WO WO90,06736 A1 6, 1990 No. 10/330,281 (US 7456,159). WO WO94, 16709 A1 8, 1994 Office Action issued on Feb. 8, 2007 by the Examiner in U.S. Appl. WO WO 98.51283 A1 11, 1998 No. 10/330,281 (US 7456,159). WO WO99, 15156 4f1999 Office Action issued on Jun. 14, 2006 by the Examiner in U.S. Appl. WO WO99, 1515.6 A1 4f1999 No. 10/330,281 (US 7456,159). WO WO99,66907 A1 12/1999 Office Action issued on Dec. 30, 2005 by the Examiner in U.S. Appl. WO WOO1/O2015 A1 1, 2001 No. 10/330,281 (US 7456,159). OTHER PUBLICATIONS Office Action issued on Jun. 29, 2005 by the Examiner in U.S. Appl. No. 10/330,281 (US 7456,159). Examiners Report issued Nov. 2008 in Chilean Patent Application No. 1332-2002. * cited by examiner U.S. Patent Jan. 11, 2011 Sheet 1 of 3 US 7,867,986 B2 - O - CombiPatch"Estradiol -O- CombiPatch"NETA - A - Ex. 1 Estradiol - A - Ex. 1 NET+NETA Time (Hours) FIGURE 1 U.S. Patent Jan. 11, 2011 Sheet 2 of 3 US 7,867,986 B2 - - CE2-1 NET A CE2-2 NETA -O EX2 NET-NETA O 24 48 72 96 time (hours) FIGURE 2 U.S. Patent Jan. 11, 2011 Sheet 3 of 3 US 7,867,986 B2 - A - Testoderm - O - Ex. 3 Testosterone - A - Ex. 3 Testosterone acetate - H Ex. 3 Total O 12 24 36 48 60 72 Time (hours) FIGURE 3 US 7,867,986 B2 1. 2 ENHANCED DRUG DELVERY IN tion, there are some applications where it is desirable to have TRANSIDERMAL SYSTEMS a greater crystal inhibiting effect. This application is a continuation of application Ser. No. SUMMARY OF THE INVENTION 09/948,107, filed Sep. 7, 2001, which claims priority to U.S. 5 Provisional Application No. 60/298,381, filed Jun. 18, 2001. One object of the invention is to overcome the disadvan BACKGROUND OF THE INVENTION tages of the known art described above. Another object of the invention is to provide a transdermal drug delivery system 1. Field of the Invention 10 that has an improved flux of steroid compared to a system of The present invention relates to transdermal drug delivery equal size. Still another object of the invention is to provide a systems. In particular, the present invention relates to trans composition that has reduced, or no, crystal formation in the dermal drug delivery systems for delivering Steroids, and to transdermal drug delivery system. methods of making and using the same. In accomplishing the foregoing and other objects, there has 2. Description of the Related Art 15 been provided according to one aspect of the present inven The use of a transdermal drug delivery system, for example tion a composition, preferably a dermal composition, result a pressure-sensitive adhesive containing a medicament, namely, a drug, as a means for administering therapeutically ing from an admixture that includes: a therapeutically effec effective amounts of the medicament is well known. Such tive amount of a pharmaceutically active agent that includes a known delivery systems involve incorporation of a medica steroid and a corresponding steroid derivative that provides a ment into a carrier Such as a polymeric and/or a pressure source of therapeutically active steroid; and a carrier for the sensitive adhesive formulation or otherforms of carriers. The pharmaceutically active agent, wherein the steroid and Ste pressure-sensitive adhesive must adhere effectively to the roid derivative are present in a weight ratio of 10:1 to 1:10 skin and permit migration of the medicament from the carrier steroid: steroid derivative. In a preferred embodiment, the through the skin and into the bloodstream of the patient. 25 steroid derivative is a steroid ester. In another preferred Steroids such as estradiol and norethindrone are especially embodiment the carrier is a polymer that includes a pressure well known for use in transdermal drug delivery systems, in sensitive adhesive. particular, as hormone replacement therapy. These steroids may be administered singularly, such as the estradiol trans According to another aspect of the invention, there has dermal drug delivery system sold under the trademark 30 been provided a method of making a composition described Vivelle(R) and Vivelle-Dot TMmanufactured by Noven Pharma above that includes forming a mixture of the steroid, corre ceuticals, Inc. of Miami, Fla. See also U.S. Pat. No. 6,221, sponding steroid derivative and carrier. Preferably, the carrier 383. Alternatively, two or more steroids may be administered is a polymer and the method further includes: forming the together, Such as the estradiol/norethindrone acetate transder 35 blend into a polymer matrix; and drying the polymer matrix to mal drug delivery system sold under the trademark Combi remove volatile solvents to form the composition. Patch(R) also manufactured by Noven Pharmaceuticals. See According to another aspect of the invention, there has also U.S. Pat. No. 6,221,383. See also U.S. Pat. No. 5,474, been provided a method of treating a human oran animal with 783. a therapeutically effective amount of a pharmaceutically Transdermal drug delivery systems with more than one 40 drug are generally more difficult to formulate in view of active agent, that includes the steps of applying to the skin of different interactions with each drug and the carrier, excipi an animal or human being, the composition described above; ents, etc., even the other drug present.
Load more

Recommended publications
  • The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus Cyanogenys
    W&M ScholarWorks Dissertations, Theses, and Masters Projects Theses, Dissertations, & Master Projects 1970 The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus cyanogenys William F. McConnell College of William & Mary - Arts & Sciences Follow this and additional works at: https://scholarworks.wm.edu/etd Part of the Physiology Commons Recommended Citation McConnell, William F., "The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus cyanogenys" (1970). Dissertations, Theses, and Masters Projects. Paper 1539624685. https://dx.doi.org/doi:10.21220/s2-1smx-cy32 This Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Dissertations, Theses, and Masters Projects by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. THE INFLUENCE OF HYPOTHALAMIC STEROID IMPLANTS ON OVULATION AND OVARIAN GROWTH AND FUNCTION IN THE IGUANID LIZARD, SCELOPORUS CYANOGENYS A Thesis Presented to The Faculty of the Department of Biology The College of William and Mary in Virginia In Partial Fulfillment Of the Requirements for the Degree of Master of Arts By William F. McConnell 1970 ProQuest Number: 10625114 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.
    [Show full text]
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • IJCB 42B(1) 166-172.Pdf
    Indian Journal of Chemistry Vol. 42B, January 2003, pp. 166-172 Synthesis and biological activity of 16-arylidene derivatives of estrone and estrone methyl ether Maninder Minu* & Dharam Paul lindal University In 5titutc of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India and G Leclercq & M Borras institut Jules Bordet, Association Hospitaliere de Bruxelles. Centre des Tumeurs de I'ULB, Rue Heger-Bordet 1- 1000, Belgiulll Received 24 April 200 I .. accepted (revised) 20 March 2002 The synthesis of 16-arylidene derivatives 3, 4, S, 6, 7. 8. 9, 10, 11, 12, 13, 14 and IS is described. These compounds have been tested at NCI, Bethesda, for their antineoplastic acti vity against the cell panel consisting of 60-ce!l lines and th e compounds 3, 4, S, 6 and 7 have also been tested for their ill vitro estrogenic / antiestrogenic activity; induction of ERE­ dependent luciferase inductio n was measured (MvLN celis). The formation of active steroids by aromatase has It was conceived that selective inhibitors of aroma­ been considered to play an important role in the de­ tase might be useful as a pharmacological tool to de­ velopment of human breast carcinoma t, at least one­ vice successful treatment approach for the hormonal third of all breast cancers establishing that. the estro­ dependent breast cancer. Our efforts were focused on gen-dependent carcinoma regresses following estro­ designing estrogen and estrogen methyl ether deriva­ 2 gen deprivation . In the postmenopausal women, the tives that might inhibit or possess antiestrogenic activ­ production of estrogen takes place in peripheral tissue ity. From these efforts, several 16-arylidine deriva­ 3 from inactive precursors by the action of aromatase .
    [Show full text]
  • Anabolic-Androgenic Steroids in Horses: Natural Presence and Underlying Biomechanisms
    ANABOLIC-ANDROGENIC STEROIDS IN HORSES: NATURAL PRESENCE AND UNDERLYING BIOMECHANISMS Anneleen Decloedt Dissertation submitted in the fulfilment of the requirements for the degree of Doctor of philosophy (PhD) in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University PROMOTER Prof. dr. ir. Lynn Vanhaecke Ghent University, Faculty of Veterinary Medicine Department of Veterinary Public Health and Food Safety Laboratory of Chemical Analysis MEMBERS OF THE READING COMMITTEE Prof. dr. James Scarth HFL Sport Science, Cambridgeshire, United-Kingdom Prof. dr. Peter Van Eenoo Ghent University, DoCoLab, Zwijnaarde, Belgium Prof. dr. Ann Van Soom Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium MEMBERS OF THE EXAMINATION COMMITTEE Dr. Ludovic Bailly-Chouriberry Laboratoires des Courses Hippiques, Verrières-le-Buisson, France Dr. Leen Van Ginkel Wageningen University, RIKILT, Wageningen, The Netherlands Prof. dr. Myriam Hesta Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium This work was funded by the Fédération Nationale des Courses Françaises (via the Laboratoire des Courses Hippiques) and executed at the Laboratory of Chemical Analysis (Faculty of Veterinary Medicine, Ghent University, Merelbeke). The author and the promoter give the authorisation to consult and to copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author. “The universe is full of magic, Just patiently waiting for our wits to grow sharper” TABLE OF CONTENTS TABLE OF CONTENTS Chapter I – General Introduction 1 1. Steroids 3 1.1 Chemical structure 1.2 (Steroid) hormones and their role in the endocrine system 1.3 Biosynthesis of steroid hormones 1.4 Anabolic-androgenic steroids (AAS) 1.5 Synthesis and absorption of the steroid precursor cholesterol 2.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Quick Determination of 105 Doping in Animal Derived Food By
    QTRAP®质谱系统对动物源食品中105种兴奋剂的快速分析 检测 Quick Determination of 105 Doping in Animal – derived Food by QTRAP® System 杨总1，陈丹2，程海燕1，李立军1，郭立海1 Yang Zong1，Chen Dan2，Cheng Haiyan1，Li Lijun1，Guo Lihai1 1 SCIEX亚太应用支持中心，上海； 2 湖北省武汉食品化妆品检验所 1 SCIEX Asia Pacific Application Support Center, Shanghai, China; 2 Wuhan Institute for Food and Cosmetic Control, Hubei Province, China; Keywords：doping；SCIEX QTRAP® 4500 系统； LC-MS/ MS；quantitative analysis 引言 在现代畜牧养殖业中，一些不法分子长期使用各种饲料添加 剂和人工合成激素类化合物，造成动物源食品中的药物残留，最 终成为食源性兴奋剂的来源[1]。运动员食用含有某些药物残留的食 物，可导致其兴奋剂检测呈阳性。国家反兴奋剂中心和世界反兴 奋剂机构（WADA）等组织机构明确规定了兴奋剂的违禁药物的种 SCIEX ExionLC™液相和SCIEX QTRAP® 4500质谱系统 类，主要包含了β-受体激动剂、固醇类激素、糖皮质激素、利尿 剂、玉米赤霉醇类等等。总体而言，兴奋剂的作用主要是对身体或 者中枢神经系统起到选择性的作用，能促进肌肉组织快速增长、增 4. 建立好了105种兴奋剂EPI二级谱库，软件自动进行匹配二级质 强机体活力和敏捷度，还可使运动员疲劳减轻，自信心增强，注意 谱图，保证筛查结果准确可靠； 力集中[2]。因此在体育赛事过程中，为了保证赛事结果的公平、公 正，在运动员食品安全保障过程中，必须对食品中兴奋剂进行严格 5. 方法现成，省去开发方法的时间，提高了工作效率； 的监控。本文针对动物源食品中的常见105种兴奋剂，建立了采用 QTRAP®系统快速筛查和定量方法，该方法完全满足在体育赛事过 1. 实验方法 程中对兴奋剂监管的分析要求。 1.1 液相色谱条件 该方案的特点和优势 色谱柱：Phenomenex Kinetex 2.6µm F5 100 Å 150×3 µm 流动相：水相（水中含有5 mM乙酸铵和0.01%甲酸），有机 1. 方法覆盖面广，包含了常见五大类β-受体激动剂、固醇类激 相为乙腈，梯度洗脱 素、糖皮质激素、利尿剂、玉米赤霉醇类兴奋剂，共105种； 1.2 质谱条件 2. 本实验详细优化了前处理过程，考察了化合物的稳定性； 扫描模式：MRM-IDA-EPI，正负离子同时扫描，MRM离子对见 3. 实验采用MRM-IDA-EPI扫描实现一针进样同时定量和定性分 表1。 析，快速灵敏，满足国内外标准品的要求； RUO-MKT-02-9756-ZH-A p 1 离子源：ESI源；离子源参数：喷雾电压（IS）：5500V（+） 2. 结果与讨论 /-4500V（-）；离子源温度：600℃；气帘气（CUR）：35psi；碰 2.1 前处理过程的优化 撞气（CAD）：Medium；雾化气（GS1）：55psi；辅助雾化气 （GS2）：60psi 本实验详细优化了前处理过程，实验结果表明在动物源食品 中酸化乙腈的提取效率最高，绝大部分化合物回收率在70%以上 1.3 样品前处理过程 （见图1、图2、图3）。由于基质的复杂性，实验比较了5种不同 称取5g样品于50 mL离心管 → 加入10 mL乙酸铵缓冲溶液混 的SPE柱的净化效率，由图4可以看出，PRIME HLB 净化效果最优 异，回收率较高。 匀 → 加入β-葡萄糖醛甙酶进行酶解 → 加入酸化乙腈进行提取， 震荡混匀后加入NaCl和Mg2SO4 → 萃取之后高速离心取上清液采用 PRIME HLB进行净化 → 吹干后复溶上机测试。 100 80 60 40 20 0 酸化叔丁基甲醚 酸化乙腈 碱化乙腈 图1.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • EURL GUIDANCE on SUBSTANCES INCLUDED in the SUBSTANCE CATEGORIES LISTED in ANNEX I of SANTE 2017/11987
    DRAFT 24 September 2019 (EURLs ANSES, BVL and WFSR) EURL GUIDANCE ON SUBSTANCES INCLUDED IN THE SUBSTANCE CATEGORIES LISTED IN ANNEX I of SANTE 2017/11987 1. A1a Stilbenes (EURL WFSR Wageningen) Cfr. Substances listed for Group A1 in the MMPR Guidance 2. A1b Antithyroid agents (EURL WFSR Wageningen) Cfr. Substances listed for Group A2 in the MMPR Guidance 3. A1c Steroids (EURL WFSR Wageningen) Cfr. Substances listed for Group A3 in the MMPR Guidance 17b-Testosterone (4-Androsten-17b-ol-3-one) 17a-Testosterone (4-Androsten-17a-ol-3-one) 17a-Boldenone 17b-Boldenone Clostebol (CLTb) (4-androsten-4-chloro-17ß-ol-3-one) CLAD (4-chloro-4-androst-3,17-dione) (chloorandrosteendion) a-Estradiol (17a-Estradiol) 17b-estradiol (17ß-estradiol) Methylboldenone (1,4-Androstadien-17a-methyl-17b-ol-3-one) 17a-Methyltestosterone (4-Androsten-17a-methyl-17b-ol-3-one) 17b-Nortestosterone (b-nandrolone) 17α-Nortestosterone (4-estren-17a-ol-3-one) Ethinylestradiol (EE2) 17a-Trenbolone 17b-Trenbolone 16b-hydroxy-stanozolol Megestrol Melengestrol Chlormadinone Medroxyprogesterone Progesterone (P1) (4-Pregnene-3,20-dione (Pregnen(4)-3,20-dione)) Androsten-17ß-ol-3-one [1,(5a)-] (17b-1-testosteron) Mestranol (Ethynylestradiol 3-methyl ether) Fluoxymesterone (FMT) (4-androsten-9a-fluoro-17a-methyl-11ß,17ß-diol-3-one) DHEA (5-androsten-3b-ol-17-one) ethyl-5ß-estrane-3a,17ß-diol [17α-] (EED) Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) Mesterolone (Androviron) Dromostanolone (Drostanolone) 2a-Methyl-5a-androstan-3a-ol-17-one
    [Show full text]
  • Progesterone 7K77 49-3265/R3 B7K770 Read Highlighted Changes Revised April, 2010 Progesterone
    en system Progesterone 7K77 49-3265/R3 B7K770 Read Highlighted Changes Revised April, 2010 Progesterone Customer Service: Contact your local representative or find country specific contact information on www.abbottdiagnostics.com Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert. Key to symbols used List Number Calibrator (1,2) In Vitro Diagnostic Medical Control Low, Medium, High Device (L, M, H) Lot Number Reagent Lot Expiration Date Reaction Vessels Serial Number Sample Cups Septum Store at 2-8°C Replacement Caps Consult instructions for use Warning: May cause an allergic reaction Contains sodium azide. Contact Manufacturer with acids liberates very toxic gas. See REAGENTS section for a full explanation of symbols used in reagent component naming. 1 NAME REAGENTS ARCHITECT Progesterone Reagent Kit, 100 Tests INTENDED USE NOTE: Some kit sizes are not available in all countries or for use on all ARCHITECT i Systems. Please contact your local distributor. The ARCHITECT Progesterone assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of progesterone in ARCHITECT Progesterone Reagent Kit (7K77) human serum and plasma. • 1 or 4 Bottle(s) (6.6 mL) Anti-fluorescein (mouse, monoclonal) fluorescein progesterone complex coated Microparticles SUMMARY AND EXPLANATION OF TEST in TRIS buffer with protein (bovine and murine) and surfactant Progesterone is produced primarily by the corpus luteum of the ovary stabilizers. Concentration: 0.1% solids. Preservatives: sodium azide in normally menstruating women and to a lesser extent by the adrenal and ProClin. cortex.1 At approximately the 6th week of pregnancy, the placenta 2-5 • 1 or 4 Bottle(s) (17.0 mL) Anti-progesterone (sheep, becomes the major producer of progesterone.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub
    US 2008 OO63698A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub. Date: Mar. 13, 2008 (54) CRYSTALLIZATION INHIBITION OF DRUGS now abandoned, which is a continuation of applica IN TRANSIDERMAL DRUG DELIVERY tion No. 10/010,342, filed on Dec. 5, 2001, now SYSTEMIS AND METHODS OF USE abandoned. (75) Inventor: Rod Lawson Hartwig, Plantation, FL (60) Provisional application No. 60/251.294, filed on Dec. (US) 5, 2000. Correspondence Address: Publication Classification Noven Pharmaceuticals, Inc. Jay G. Kolman, Esq. (51) Int. Cl. 11960 S.W. 144 Street A6II 3/56 (2006.01) A6F 3/00 (2006.01) Miami, FL 33186 (US) A6IP 43/00 (2006.01) (73) Assignee: NOVEN PHARMACEUTICALS, A6F 3/02 (2006.01) INC. (52) U.S. Cl. ........................... 424/448; 424/449; 514/170 (57) ABSTRACT Appl. No.: 11/897,189 (21) The invention relates to compositions and methods for (22) Filed: Aug. 29, 2007 making a transdermal drug delivery system capable of achieving substantially zero-order kinetics for delivery of Related U.S. Application Data the active agent over a period of time in excess of 24 hours and at least 72 hours, comprising a pharmaceutically accept (63) Continuation of application No. 10/751,152, filed on able active agent carrier and a rosin ester which provides a Jan. 2, 2004, now abandoned, which is a continuation crystal inhibiting and drug stabilizing effect on the active of application No. 10/353,624, filed on Jan. 29, 2003, agents incorporated therein. 13 2 2 Patent Application Publication Mar.
    [Show full text]
  • 有限公司 Testosterones
    ® 伊域化學藥業（香港）有限公司 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD Rm 1006, 10/F, Hewlett Centre, Tel: (852) 25412772 (4 lines) No. 52-54, Hoi Yuen Road, Fax: (852) 25423444 / 25420530 / 21912858 Kwun Tong, E-mail: [email protected] YICK -VIC 伊域 Kowloon, Hong Kong. Site: http://www.yickvic.com Testosterones Product Code CAS Product Name MIS-42658 1043-10-3 (8S,9S,10R,11S,13S,14S,17S)-11,17-DIHYDROXY-10,13,17-TRIMETHYL-2,6,7,8,9,11,12,14,15,16-DECAHYDRO-1H-CYCLOPENTA[A]PHENA NTHREN-3-ONE UNIE-13864 564-35-2 11-KETOTESTOSTERONE PH-1081U 17-ALPHA-HYDROXYTESTOSTERONE ACETATE MIS-39218 51154-09-7 17ALPHA-METHYLTESTOSTERONE 4,5-EPOXIDE PH-1121 72-63-9 17BETA-HYDROXY-17-METHYLANDROSTA-1,4-DIEN-3-ONE MIS-34565 5585-85-3 17BETA-HYDROXY-17-METHYLANDROSTA-4,6-DIEN-3-ONE PH-1081S 17BETA-HYDROXYANDROST-1-ENE-3-ONE TETRAHYDROPYRANYL ETHER PH-1081VA 1-TESTOSTERONE ETHYL CARBONATE PH-1081VB 1-TESTOSTERONE METHYL CARBONATE PH-1081VC 1-TESTOSTERONE PROPYL CARBONATE PH-1081HB 1-TESTOSTERONE UNDECANOATE UNIE-15172 2141-17-5 4-HYDROXYTESTOSTERONE UNIE-13597 62-99-7 6BETA-HYDROXYTESTOSTERONE SPI-4361 14531-84-1 6-DEHYDRO-19-NORTESTOSTERONE PH-1081PK 1057-07-4 ANDROSTANOLONE 17-BENZOATE Copyright © 2018 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Page 1 of 3 Product Code CAS Product Name PH-1133 1605-89-6 BOLASTERONE UNIE-8525 CHLORDEHYDROMETHYLTESTOSTERONE PH-1081JA 1093-58-9 CLOSTEBOL PH-1081JB 855-19-6 CLOSTEBOL ACETATE SPI-0027GA 481-30-1 EPITESTOSTERONE SPI-0027GB EPITESTOSTERONE ACETATE PH-1081K 434-03-7 ETHISTERONE PH-1136B 76-43-7
    [Show full text]